Personalis (NASDAQ:PSNL) Stock Price Down 4.1% - What's Next?

Key Points

• Personalis, Inc. shares dropped 4.1% on Friday, trading as low as $5.85, with a significant decline in trading volume of 90% from its average session.
• Several analysts have revised their ratings, with Wall Street Zen downgrading the stock from "hold" to "sell," while consensus estimates indicate a "Buy" rating and an average price target of $7.42.
• The company reported a quarterly earnings loss of ($0.23) per share, surpassing estimates but falling short on revenue, indicating a negative net margin of 113.70%.

Personalis, Inc. (NASDAQ:PSNL - Get Free Report) shares fell 4.1% during mid-day trading on Friday . The stock traded as low as $5.87 and last traded at $5.85. 104,175 shares traded hands during mid-day trading, a decline of 90% from the average session volume of 1,045,348 shares. The stock had previously closed at $6.10.

Analysts Set New Price Targets

Several research firms recently issued reports on PSNL. Wall Street Zen downgraded Personalis from a "hold" rating to a "sell" rating in a research note on Saturday, August 9th. BTIG Research set a $6.00 target price on Personalis in a research report on Wednesday, August 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $8.50 target price on shares of Personalis in a research report on Monday, September 8th. Five research analysts have rated the stock with a Buy rating, According to data from MarketBeat, Personalis presently has a consensus rating of "Buy" and an average target price of $7.42.

Personalis Stock Up 0.4%

The company has a market cap of $522.77 million, a price-to-earnings ratio of -4.69 and a beta of 1.76. The firm has a 50 day moving average price of $5.46 and a two-hundred day moving average price of $4.89.

Personalis (NASDAQ:PSNL - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.02. The company had revenue of $17.20 million during the quarter, compared to analysts' expectations of $20.12 million. Personalis had a negative return on equity of 47.57% and a negative net margin of 113.70%. Personalis has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. On average, equities analysts expect that Personalis, Inc. will post -1.4 earnings per share for the current year.

Institutional Investors Weigh In On Personalis

Several large investors have recently added to or reduced their stakes in PSNL. Legal & General Group Plc bought a new position in Personalis in the second quarter worth approximately $30,000. Point72 Asia Singapore Pte. Ltd. bought a new position in Personalis in the fourth quarter worth approximately $28,000. Ameritas Investment Partners Inc. bought a new position in Personalis in the second quarter worth approximately $34,000. BNP Paribas Financial Markets boosted its holdings in Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company's stock worth $42,000 after acquiring an additional 5,177 shares in the last quarter. Finally, Alpha Wealth Funds LLC bought a new position in Personalis in the second quarter worth approximately $66,000. Institutional investors and hedge funds own 61.91% of the company's stock.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.